Department of Anesthesiology, Duke University Medical Center, Box 3094, Durham, NC 27710, USA.
Br J Anaesth. 2012 Mar;108(3):374-83. doi: 10.1093/bja/aer509. Epub 2012 Feb 3.
Nausea and vomiting occur commonly during and after Caesarean delivery (CD) performed under neuraxial anaesthesia. Metoclopramide is a prokinetic agent reported to be safe in parturients. This meta-analysis assesses the efficacy of metoclopramide for prophylaxis against intra- and postoperative nausea and vomiting (IONV and PONV) in parturients undergoing CD under neuraxial anaesthesia. We performed a literature search of MEDLINE (1966-2011), Cochrane Central Register of Controlled Trials, EMBASE (1947-2011), Google scholar, and CINAHL for randomized controlled trials which compared metoclopramide with placebo in women having CD under neuraxial anaesthesia. Eleven studies with 702 patients were included in the analysis. Administration of metoclopramide (10 mg) resulted in a significant reduction in the incidence of ION and IOV when given before block placement [relative risk (RR) (95% confidence interval, 95% CI)=0.27 (0.16, 0.45) and 0.14 (0.03, 0.56), respectively] or after delivery [RR (95% CI)=0.38 (0.20, 0.75) and 0.34 (0.18, 0.66), respectively]. The incidence of early (0-3 or 0-4 h) PON and POV [RR (95% CI)=0.47 (0.26, 0.87) and 0.45 (0.21, 0.93), respectively] and overall (0-24 or 3-24 h) PON (RR 0.69; 95% CI 0.52, 0.92) were also reduced with metoclopramide. Extra-pyramidal side-effects were not reported in any patient. In conclusion, this review suggests that metoclopramide is effective and safe for IONV and PONV prophylaxis in this patient population. Given the quality of the studies and the infrequent use of neuraxial opioids, these results should be interpreted with caution in current practice and further studies are needed to confirm those findings.
在椎管内麻醉下施行剖宫产术(CD)期间和之后,常发生恶心和呕吐。胃复安是一种被报道在产妇中安全的促动力药物。本荟萃分析评估了胃复安预防椎管内麻醉下施行 CD 的产妇术中及术后恶心和呕吐(IONV 和 PONV)的疗效。我们检索了 MEDLINE(1966-2011)、Cochrane 对照试验中心注册库、EMBASE(1947-2011)、Google 学术和 CINAHL,以查找比较椎管内麻醉下施行 CD 的产妇接受胃复安与安慰剂的随机对照试验。纳入了 11 项研究共 702 例患者的分析。胃复安(10 mg)在阻滞前给予 [相对危险度(RR)(95%置信区间,95%CI)=0.27(0.16,0.45)和 0.14(0.03,0.56)]或在分娩后给予时,显著降低了 ION 和 IOV 的发生率;RR(95%CI)分别为 0.38(0.20,0.75)和 0.34(0.18,0.66)。PON 和 POV 的早发(0-3 或 0-4 h)[RR(95%CI)=0.47(0.26,0.87)和 0.45(0.21,0.93)]和总体(0-24 或 3-24 h)PON 的发生率[RR 0.69;95%CI 0.52,0.92]也降低了。没有患者报告出现锥体外系副作用。总之,本综述表明,在该患者人群中,胃复安对 IONV 和 PONV 预防有效且安全。考虑到研究质量和椎管内阿片类药物的应用频率较低,在当前实践中应谨慎解释这些结果,需要进一步的研究来证实这些发现。